Key statistics dashboard for FibroBiologics, Inc. Common Stock (FBLG). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair.
Stock Data
| Price | $1.43 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.25 |
| Price / Book | 1.20 |
| P/S | 0.00 |
| P/FCF | -0.21 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 2.64 |
| Quick Ratio | 2.64 |
| Cash Ratio | 1.59 |
| Debt / Equity | 0.32 |
| Debt / Assets | 18.44% |
| Interest Coverage | -77.81 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -11.28 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.23 |
| Cash per share | 0.93 |
| FCF per share | -3.92 |
| Tangible Book Value per share | 1.23 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.50 |
Related companies: ADTX · AIMD · APLM · ATHA · CTXR · DARE · HOTH
Explore sector: Healthcare · Biotechnology
More sections of FBLG: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks